Drug Makers Win Summary Judgment on De Minimis Price Discrimination Claim


A recent case reminds us that price discrimination under the Robinson-Patman Act may be so de minimis that it is not actionable.

In Drug Mart Pharmacy Corp. v. American Home Products Corp. (No. 1:93-cv-05148-ILG-SMG) (August 16, 2012) (a so-called secondary line discrimination case involving disfavored retailers), retail pharmacies brought a Robinson-Patman Act price discrimination claim against various drug manufacturers, alleging that the manufacturers had effectively given price breaks to hospitals, HMOs, and mail order pharmacies but not to the smaller retailers. Plaintiffs argued that they could identify specific customers lost to competitors as a result of the price discrimination, and selected a test sample of plaintiffs to evaluate.

Upon evaluation, the 28 sample plaintiffs were only able to match 5,147 potential lost customers (about 3% of their customer base) and 15,043 potential lost transactions.

On these facts, the court concluded that the plaintiffs had failed to demonstrate an anti-competitive effect or antitrust injury. Although FTC v. Morton Salt Co., 334 U.S. 37 (1948), allows an inference of anti-competitive effect where there is a significant price difference over a substantial period of time, this presumption is subject to rebuttal, and here the plaintiffs themselves undertook an extensive, costly, and time-consuming effort to trace the customers they claim to have lost to favored purchasers because of price discrimination, but “essentially c[a]me up empty.”

Additionally, plaintiffs could not show antitrust injury, because they could not match up any alleged losses with gains to favored customers — at least not beyond a de minimis amount.

Price discrimination is not per se unlawful, and winning a price discrimination case, while not impossible, is in fact very difficult.

[View source.]


Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Howard Ullman, Orrick, Herrington & Sutcliffe | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.